Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
iSpecimen Inc (ISPC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: ISPC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.71% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.10M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 948060 | Beta 1.77 | 52 Weeks Range 1.02 - 11.40 | Updated Date 04/5/2025 |
52 Weeks Range 1.02 - 11.40 | Updated Date 04/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -18.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -91.66% | Operating Margin (TTM) -64.07% |
Management Effectiveness
Return on Assets (TTM) -44.26% | Return on Equity (TTM) -109.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 524300 | Price to Sales(TTM) 0.11 |
Enterprise Value 524300 | Price to Sales(TTM) 0.11 | ||
Enterprise Value to Revenue 0.05 | Enterprise Value to EBITDA 0.43 | Shares Outstanding 962637 | Shares Floating 850827 |
Shares Outstanding 962637 | Shares Floating 850827 | ||
Percent Insiders 14.5 | Percent Institutions 3.71 |
Analyst Ratings
Rating 5 | Target Price 5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
iSpecimen Inc
Company Overview
History and Background
iSpecimen Inc. was founded in 1999. It provides a marketplace for human biospecimens, connecting researchers with biobanks and healthcare organizations to facilitate research and development. Initially focused on facilitating research in specific disease areas, iSpecimen has evolved into a broader platform connecting numerous suppliers and researchers globally.
Core Business Areas
- iSpecimen Marketplace: The core business is operating an online marketplace that connects researchers needing human biospecimens with suppliers (biobanks, hospitals, etc.) that have them available. It handles the logistics, quality control, and contracting necessary for these transactions.
- Services: iSpecimen offers services that complement its marketplace, including custom collection, prospective collections, and specimen processing. These services enhance the value proposition for both researchers and suppliers.
Leadership and Structure
iSpecimen is led by a management team with experience in healthcare, technology, and biospecimen management. The organizational structure includes departments responsible for sales, marketing, technology, operations, and finance.
Top Products and Market Share
Key Offerings
- Biospecimen Marketplace: This is iSpecimen's primary offering, connecting researchers with a broad range of human biospecimens (blood, tissue, etc.). They manage the ordering, contracting, and shipping for Researchers. While exact market share data is hard to quantify as the overall Biospecimen market is highly fragmented, iSpecimen reports that they have over 200 healthcare provider organizations and thousands of researchers utilizing their platform globally. Competitors: Precision for Medicine, BioIVT, Discovery Life Sciences.
- iSpecimen OnDemand: Enables researchers to initiate prospective sample collection projects. No reliable market share information available. Competitors: Precision for Medicine, BioIVT, Discovery Life Sciences.
Market Dynamics
Industry Overview
The human biospecimen market is growing due to increasing research and development in pharmaceuticals, diagnostics, and personalized medicine. Key trends include the increasing demand for high-quality, well-annotated biospecimens and the growing adoption of online marketplaces for biospecimen procurement.
Positioning
iSpecimen is positioned as a leading provider of an online marketplace for human biospecimens, offering a broad network of suppliers and a comprehensive suite of services. Its competitive advantages include its extensive network, technology platform, and expertise in biospecimen management.
Total Addressable Market (TAM)
Estimates place the global biospecimen market in the tens of billions of dollars, with continuous expansion expected. iSpecimen aims to grow its share of this market by expanding its supplier and researcher network, improving its technology platform, and enhancing its service offerings.
Upturn SWOT Analysis
Strengths
- Extensive supplier network
- Technology platform for biospecimen procurement
- Comprehensive suite of services
- Strong brand recognition within the research community
Weaknesses
- Dependence on research funding cycles
- Competition from larger, more established biospecimen providers
- Need for continuous investment in technology and infrastructure
- High customer concentration
Opportunities
- Expansion into new geographic markets
- Development of new biospecimen-related services
- Partnerships with pharmaceutical and diagnostic companies
- Increased demand for personalized medicine
Threats
- Economic downturns impacting research funding
- Changes in regulations governing biospecimen procurement
- Emergence of new competitors
- Data privacy and security concerns
Competitors and Market Share
Key Competitors
- PFWD
- BIOV
- QLGN
Competitive Landscape
iSpecimen's competitive advantages include its marketplace platform and network. Disadvantages may include its smaller size and limited financial resources compared to some competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: iSpecimen has experienced growth in its marketplace and service offerings, driven by increasing demand for biospecimens for research.
Future Projections: Analyst estimates suggest continued revenue growth for iSpecimen, but profitability may remain a challenge in the near term. This data will require access to analyst reports.
Recent Initiatives: Recent initiatives likely include expanding its supplier network, enhancing its technology platform, and developing new service offerings. Refer to press releases and investor presentations for specific details.
Summary
iSpecimen operates a valuable marketplace for biospecimens, connecting researchers and suppliers efficiently. The company's growth trajectory is promising, driven by increasing research demand. However, profitability remains a challenge, and competition is fierce. iSpecimen needs to focus on scaling its operations and managing expenses to achieve sustainable profitability.
Similar Companies
DGX
Quest Diagnostics Incorporated
DGX
Quest Diagnostics Incorporated
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
QLGN
Qualigen Therapeutics Inc
QLGN
Qualigen Therapeutics Inc
Sources and Disclaimers
Data Sources:
- iSpecimen Inc. website
- SEC filings
- Market research reports
- Press releases
- Analyst reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change rapidly. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iSpecimen Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2021-06-17 | CEO, Treasurer, Secretary & Director Mr. Robert Bradley Lim | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 53 | Website https://ispecimen.com |
Full time employees 53 | Website https://ispecimen.com | ||
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.